Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co selects Ireland for USD 280m biologics site

Merck & Co locates its site for a new vaccines and biologics facility in the Republic of Ireland with an investment of USD 280m

US-based Merck & Co has located its site for a new vaccines and biologics facility in the Republic of Ireland with an investment EUR 200m (USD 280m).

The plant is scheduled to begin operations by 2011 and will employ 170 people across production, engineering, R&D, quality control, management and administration.

Ireland's Industrial Development Agency (IDA) said that Merck & Co's decision was a very significant consolidation of Ireland's high profile position as a successful location for substantial biotechnology global investments.

The 65-acre IDA Business and Technology Park is located in Carlow and will be Ireland's first stand-alone human vaccine project. The new facility will perform formulation and sterile filling activities, as well as conducting R&D operations to support recently launched vaccines and future projects.

According to the IDA, Merck & Co, which operates as Merck, Sharp and Dohme in the country, will also recruit local academic talent to leverage opportunities in developing biologic products.

Merck & Co, who already has two other plants in Ireland, joins Abbott which operates seven sites, Johnson & Johnson with six, Pfizer with five and Schering Plough and GlaxoSmithKline (GSK) which both have four sites.

29th November 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics